Authors


James C. Wernz, MD

Latest:

Epidemic Kaposi’s Sarcoma

Kaposi’s sarcoma (KS) is the most common malignancy associated with human immunodeficiency virus-1 (HIV-1) infection and can result in significant morbidity. The clinical course of KS is quite variable, although for the


James C. Yao, MD

Latest:

Gastrointestinal Neuroendocrine Tumors: Slow but Steady Progress

In spite of recent encouraging developments in the setting of GI neuroendocrine tumors, many clinical questions remain to be answered and will be highlighted in this commentary.


James Carmichael, BSc, MBChB, MD, FRCP

Latest:

UFT Plus Leucovorin vs 5-FU Plus Leucovorin for Metastatic Colorectal Cancer

An open-label, randomized phase III trial has been established to compare the efficacy and safety profile of tegafur and uracil (UFT) plus leucovorin with fluorouracil (5-FU) plus leucovorin as first-line chemotherapy for


James Cripe, MD

Latest:

Anti-Angiogenesis Therapy in Gynecologic Malignancies

The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.


James D. Ahlgren, MD

Latest:

Chemotherapy for Resectable and Advanced Pancreatic Cancer

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single


James D. Cox, MD

Latest:

Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer

Prophylactic cranial irradiation(PCI) in patients with locallyadvanced non–small-cell lungcancer (NSCLC) remains an area ofcontroversy. Dr. Gore has provided areview of the literature, including randomizedand nonrandomized studiesand, in particular, the ongoing RadiationTherapy Oncology Group trial(RTOG 0214), which is randomizingNSCLC patients to PCI or observation.


James D. Luketich, MD

Latest:

Management of Barrett's Esophagus

Barrett's esophagus represents replacement of normal distal esophageal squamous epithelium with specialized columnar epithelium containing goblet cells. Typically arising in the setting of chronic gastroesophageal reflux disease, the presence of Barrett's esophagus carries a 50- to 100-fold increased risk of developing esophageal cancer. Risk factors include male sex, smoking history, obesity, Caucasian ethnicity, age > 50 and > 5-year history of reflux symptoms. Aggressive medical or surgical antireflux therapy may ameliorate symptoms, but have not yet been proven to affect the risk of developing esophageal adenocarcinoma in randomized trials. Although dysplasia is an imperfect biomarker for the development of subsequent malignancy, random sampling of esophageal tissue for dysplasia remains the clinical standard. There have been no studies to establish that endoscopic screening/surveillance programs decrease the rates of death from cancer. Fit patients with Barrett's esophagus and high-grade dysplasia should undergo esophagectomy to prevent the risk of developing esophageal adenocarcinoma. For non–operative candidates, endoscopic ablative approaches may represent a reasonable therapeutic alternative.


James Dougherty, MD

Latest:

Stress and Burnout in Oncology

This article identifies the professional stressors experienced by nurses, house staff, and medical oncologists and examines the effect of stress and personality attributes on burnout scores. A survey was conducted of 261 house


James E. Fitzpatrick, MD

Latest:

Metastatic Malignant Melanoma From an Unknown Primary Presenting as a Large Axillary Mass

The patient is an otherwise healthy male transferred from an outside hospital with a newly diagnosed melanoma from an unknown primary presenting as a large, left axillary mass.


James E. Montie, MD

Latest:

Therapeutic Radiation in Patients With a Rising Post-Prostatectomy PSA Level

Drs. Forman and Velasco provide a timely and thorough review of the maturing concept of applying radiation therapy to the prostatic fossa after radical prostatectomy. The guidelines for therapy continue to evolve because of the increasing reliance on blood prostate-specific antigen (PSA) level for both detecting a recurrence of disease and evaluating response to radiotherapy.


James E. Ruffer, MD

Latest:

Clinical Uses of Radiosurgery

Radiosurgery uses stereotactic targeting methods to precisely deliver highly focused, large doses of radiation to small intracranial tumors and arteriovenous malformations (AVMs). This article reviews the most common


James E. Spellman, MD, FACS

Latest:

Role of Sentinel Node Biopsy in the Management of Malignant Melanoma

The use of elective lymph node dissection for intermediate-thickness melanoma has remained controversial. The technique of sentinel node biopsy (intraoperative lymphatic mapping and selective lymphadenectomy) has been


James E. Thompson, MD

Latest:

The Role of Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Supportive care remains the mainstay of therapy for patients withmyelodysplastic syndrome (MDS). Although allogeneic bone marrowtransplantation is the only known curative therapy for MDS, its risksmake this treatment prohibitive in many patients, who tend to be olderand have other medical problems. With advances in hematopoietic stemcell transplantation (HSCT), we can offer transplant to an increasingnumber of patients. It is, however, necessary to assess each patient andhis or her disease individually and evaluate prognostic factors, treatmentoptions, appropriateness of HSCT, and, if appropriate, type andtiming of HSCT. We will review the data on HSCT in MDS in order toexamine each of these issues and clarify the decision-making process.


James E. Wooldridge, MD

Latest:

Corticosteroids in Advanced Cancer

Despite the fact that there are only a few controlled trials demonstrating the benefits associated with the use of corticosteroids in specific situations, these agents are administered frequently to patients with advanced cancer. Corticosteroids may be used alone or as adjuvants in combination with other palliative or antineoplastic treatments. For example, corticosteroids may help prevent nausea, vomiting, and hypersensitivity reactions to treatment with chemotherapy or radiation. They are also commonly used as appetite stimulants in patients with advanced cancer. In the adjuvant setting, corticosteroids help to alleviate pain in advanced cancer patients, including specific situations such as back pain related to epidural compression. This article reviews the evidence supporting the use of corticosteroids in a broad range of situations seen in patients with advanced cancer. [ONCOLOGY 15(2):225-236, 2001]


James F. Bishop, MD, MBBS

Latest:

Paclitaxel as First-Line Treatment for Metastatic Breast Cancer

When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard


James Fick, MD

Latest:

Commentary (Fick/Gutin): Current Management of Meningiomas

Surgical resection has been the preferred treatment for meningiomas since the era of the pioneering neurosurgeon, Harvey Cushing. The great majority of these tumors are histologically benign, circumscribed lesions that grow slowly and tend to compress and displace, rather than invade, the surrounding intracranial structures. In contrast to the intrinsic brain tumors of glial origin, most meningiomas have well-defined borders, enabling the surgeon to dissect the tumor capsule from the arachnoid lining of the adjacent brain, blood vessels, and cranial nerves. Consequently, complete removal can be accomplished without needing to sacrifice functional tissue. In these cases, surgery is often curative, and associated with the preservation of, if not improvements in, the neurological condition.


James Fitzpatrick, MD

Latest:

A Case of Merkel Cell Carcinoma

The University of Colorado Health Sciences Center holds weekly second opinion conferences focusing on cancer cases that represent most major cancer sites. Patients seen for second opinions are evaluated by an oncologist. Their history, pathology, and radiographs are reviewed during the multidisciplinary conference, and then specific recommendations are made. These cases are usually challenging, and these conferences provide an outstanding educational opportunity for staff, fellows, and residents in training.


James Flory, MD

Latest:

Diabetes Management in Cancer Patients

Hyperglycemia is a common challenge during cancer treatment and palliation. In addition, many patients with pre-existing type 1 or type 2 diabetes undergoing cancer treatment develop iatrogenic hyperglycemia with unique features.


James G. Jakowatz, MD

Latest:

Docetaxel and Vinorelbine Plus GM-CSF in Malignant Melanoma

Patients having locoregional or metastatic melanoma have a poorprognosis, with 50% to 100% of patients dying from the disease within5 years. Current chemotherapy regimens offer limited benefits to thesepatients, and more effective and less toxic treatments are needed. Wetherefore piloted a study of docetaxel (Taxotere), vinorelbine(Navelbine), granulocyte-macrophage colony-stimulating factor(GM-CSF, sargramostim [Leukine]), or the DVS regimen, in patientswith stage IV melanoma. Eight patients were treated after previousbiochemotherapy and two patients were given the regimen as an initialtreatment. The DVS regimen consisted of docetaxel at 40 mg/m2 IVover 1 hour, vinorelbine at 30 mg/m2 IV over 6 to 10 minutes every 14days, and GM-CSF at 250 mg/m2 SC on days 2 to 12. No grade 3 or 4toxicities were encountered. Of the 10 patients evaluable for response, 5were partial responders (50% response rate). Time to progression for the10 cases ranged from 2 to 26+ months (median: 8 months). The DVSregimen was active against advanced melanoma in both previously treatedand untreated patients. A larger study to confirm the activity of the DVSregimen for stage IV melanoma is currently under way.


James H. North, Jr, MD, FACS

Latest:

Role of Sentinel Node Biopsy in the Management of Malignant Melanoma

The use of elective lymph node dissection for intermediate-thickness melanoma has remained controversial. The technique of sentinel node biopsy (intraoperative lymphatic mapping and selective lymphadenectomy) has been


James Huang, MD

Latest:

How We Treat Tumor Lysis Syndrome

When tumor cells are rapidly broken down and their contents released into the extracellular space, the released ions and compounds can cause metabolic disturbances too great to be neutralized by the body's normal mechanisms.


James Ito, Jr, MD

Latest:

Infectious Complications

Infections are among the most common, potentially serious complications of cancer and its treatment.



James J. Lee, MD, PhD

Latest:

The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.


James Khatcheressian, MD

Latest:

Giving Honest Information to Patients With Advanced Cancer Maintains Hope

Oncologists often do not give honest prognostic and treatment-effect information to patients with advanced disease, trying not to “take away hope.” The authors, however, find that hope is maintained when patients with advanced cancer are given truthful prognostic and treatment information, even when the news is bad.


James L. Abbruzzese, MD, FACP

Latest:

Novel Approaches to ‘Borderline Resectable’ Pancreatic Tumors

The authors describe the case of a 40-year-old man with an adenocarcinoma of the pancreatic head with involvement of the superior mesenteric vein–portal vein (SMV-PV) confluence resulting in limited occlusion.


James L. Gulley, MD, PhD, FACP

Latest:

Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers

Radiation is often considered immunosuppressive, an activity that is most likely a result of the complex interplay of hormesis and the abscopal effect. The abscopal effect, also called the “distant bystander” effect, is a paradoxical effect of radiation on cellular systems whereby local radiation may have an antitumor effect on tumors distant from the site of radiation.


James L. Levenson, MD

Latest:

Depression in Cancer Patients

Drs. Jeremy Winell and AndrewRoth have provided a niceoverview of the diagnosis andtreatment of depression in cancer patients.The views they express are bothwidely accepted and applicable to otherserious medical illnesses as well.They remind us of the challenge ofmaking a valid diagnosis of depressionin cancer patients, since all of thesomatic symptoms of depression (eg,anorexia, fatigue, insomnia) may insome patients represent symptoms ofcancer or cancer treatment rather thandepression.


James L. Mulshine, MD

Latest:

Shared Decision Making and Screening: An Ongoing Dialogue Informed by Data

A state of equipoise now exists for various surgical options in the treatment of early lung cancer, underscoring the need for shared decision making.


James L. Wade Iii, MD

Latest:

Managed Care’s Effects on Community Clinical Research

Managed care is transforming numerous aspects of health care delivery, and the specialty of oncology, in particular, is being increasingly affected for several reasons.